Insulet Co. (NASDAQ:PODD) Expected to Earn Q4 2019 Earnings of $0.11 Per Share

Share on StockTwits

Insulet Co. (NASDAQ:PODD) – Equities researchers at Jefferies Financial Group boosted their Q4 2019 earnings per share (EPS) estimates for Insulet in a research report issued to clients and investors on Tuesday, November 5th. Jefferies Financial Group analyst R. Denhoy now forecasts that the medical instruments supplier will post earnings per share of $0.11 for the quarter, up from their previous forecast of $0.06. Jefferies Financial Group currently has a “Buy” rating and a $140.00 target price on the stock. Jefferies Financial Group also issued estimates for Insulet’s Q1 2020 earnings at $0.07 EPS, Q2 2020 earnings at $0.15 EPS, Q3 2020 earnings at $0.30 EPS, Q4 2020 earnings at $0.36 EPS, FY2020 earnings at $0.88 EPS and FY2021 earnings at $1.95 EPS.

Other equities analysts also recently issued research reports about the stock. BMO Capital Markets lifted their target price on shares of Insulet from $130.00 to $150.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 6th. Canaccord Genuity downgraded shares of Insulet from a “buy” rating to a “hold” rating and lifted their price target for the company from $135.00 to $145.00 in a research note on Friday, October 18th. Robert W. Baird lifted their price target on shares of Insulet from $165.00 to $170.00 and gave the company an “outperform” rating in a research note on Wednesday. UBS Group downgraded shares of Insulet from a “buy” rating to a “neutral” rating and lifted their price target for the company from $155.00 to $160.00 in a research note on Friday, October 4th. They noted that the move was a valuation call. Finally, ValuEngine downgraded shares of Insulet from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Ten analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $151.71.

Shares of Insulet stock opened at $169.46 on Friday. Insulet has a fifty-two week low of $70.80 and a fifty-two week high of $171.96. The company’s 50 day moving average price is $154.75 and its two-hundred day moving average price is $130.77. The firm has a market capitalization of $8.73 billion, a P/E ratio of 3,389.20 and a beta of 0.96. The company has a debt-to-equity ratio of 2.43, a current ratio of 4.72 and a quick ratio of 3.91.

Insulet (NASDAQ:PODD) last issued its earnings results on Tuesday, November 5th. The medical instruments supplier reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). Insulet had a net margin of 2.38% and a return on equity of 9.46%. The company had revenue of $192.12 million during the quarter, compared to analyst estimates of $179.50 million. During the same quarter in the prior year, the business earned $0.03 EPS. The business’s quarterly revenue was up 27.2% on a year-over-year basis.

In other news, CEO Shacey Petrovic sold 649 shares of Insulet stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $152.40, for a total transaction of $98,907.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Michael P. Spears sold 4,153 shares of Insulet stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $146.12, for a total transaction of $606,836.36. Following the transaction, the senior vice president now owns 22,626 shares of the company’s stock, valued at $3,306,111.12. The disclosure for this sale can be found here. Insiders have sold 5,491 shares of company stock valued at $806,124 over the last quarter. Corporate insiders own 3.50% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of PODD. Cortina Asset Management LLC grew its holdings in shares of Insulet by 5.4% during the second quarter. Cortina Asset Management LLC now owns 2,447 shares of the medical instruments supplier’s stock valued at $292,000 after buying an additional 126 shares during the last quarter. Harbour Capital Advisors LLC boosted its holdings in Insulet by 21.4% during the second quarter. Harbour Capital Advisors LLC now owns 6,489 shares of the medical instruments supplier’s stock worth $775,000 after purchasing an additional 1,144 shares during the last quarter. HMS Capital Management LLC purchased a new position in Insulet during the second quarter worth about $195,000. First Hawaiian Bank boosted its holdings in Insulet by 2,758.3% during the second quarter. First Hawaiian Bank now owns 1,715 shares of the medical instruments supplier’s stock worth $205,000 after purchasing an additional 1,655 shares during the last quarter. Finally, Gradient Investments LLC boosted its holdings in Insulet by 68.1% during the second quarter. Gradient Investments LLC now owns 10,620 shares of the medical instruments supplier’s stock worth $1,268,000 after purchasing an additional 4,304 shares during the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.

Recommended Story: How is the S&P 500 index different from the DJIA?

Earnings History and Estimates for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.